People channel feed

AI-fo­cused biotech in­sitro cuts 22% of staff, cit­ing 'tu­mul­tuous mar­ket'

2 days ago
AI

Blood can­cer biotech Vor Bio ends clin­i­cal work, lays off 95% of staff

2 days ago

Eu­rope pledges €500M to at­tract glob­al sci­ence tal­ent

4 days ago
Pharma

Ex­clu­sive: Degra­da­tion start­up rais­es $39M for piv­ot to PRO­TACs and clin­i­cal en­try

5 days ago
Financing
Startups

Bris­tol My­ers to lay off over 500 work­ers in New Jer­sey

5 days ago
Pharma

Bris­tol My­ers to close cell ther­a­py site in Illi­nois as part of on­go­ing cost cuts

Last week
Cell/Gene Tx
Manufacturing

Ex­its con­tin­ue at FDA, as more staff in drug of­fice fol­low fired col­leagues out the door

Last week
FDA+

The End­points Slack in­ter­view: Arc In­sti­tute's Patrick Hsu on in­vest­ing, AI and new ways of re­search

Last week
AI

Oc­ta­gon Ther­a­peu­tics shuts down af­ter 'un­re­solved bi­ol­o­gy ques­tion­s'

Last week
Startups

Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build

Last week

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

3 weeks ago
R&D
Cell/Gene Tx

As­traZeneca CEO says Eu­rope is 'falling be­hind' on R&D and man­u­fac­tur­ing in­vest­ments

3 weeks ago
Pharma

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

3 weeks ago
Pharma

Gala­pa­gos CEO Paul Stof­fels to step down, for­mer Neumo­ra chief to lead spin­out

3 weeks ago

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

3 weeks ago
R&D

Ex­clu­sive: Charm Ther­a­peu­tic­s' founder steps down as CEO, as AI biotech eyes clin­ic in 2026

4 weeks ago
AI

Mur­al On­col­o­gy ends clin­i­cal de­vel­op­ment, lays off most work­ers

4 weeks ago
R&D

Re­cruiters say some bio­phar­mas pause hir­ing as they strug­gle to make sense of on­go­ing un­cer­tain­ty

5 weeks ago
Startups

Vac­cines, obe­si­ty drugs, job cuts: Take­aways from RFK Jr.'s first net­work in­ter­view as HHS chief

5 weeks ago
Pharma

Q&A: Lund­beck’s head of R&D on let­ting ‘bi­ol­o­gy speak’ in neu­ro­science

Last month
R&D

‘This is self-in­flict­ed’: Leerink’s David Risinger on the mar­ket shock and hits to bio­phar­ma

Last month
FDA+

Q&A: A con­ver­sa­tion with GLP-1 co-dis­cov­er­er Jens Ju­ul Holst on the fu­ture of in­cretin-based drugs

Last month

Q&A: David Liu talks about sci­ence un­der pres­sure, teas­es “dis­ease-ag­nos­tic” gene edit­ing

Last month

Re­lay Ther­a­peu­tics does third round of lay­offs in nine months, af­fect­ing about 70 em­ploy­ees

Last month
1234 Next page Last page
A service from the Financial Times